Literature DB >> 2277299

Heart transplantation in patients with malignant disease.

J M Armitage1, R L Kormos, B P Griffith, F J Fricker, R L Hardesty.   

Abstract

We have traditionally pushed the limits of conservative candidate criteria for heart transplantation. We have been gratified by our results in the aged, the diabetic, and the mortally ill. Our inclusion of patients with malignant disease underscores our philosophy to include patients as candidates for transplantation for whom the procedure has reasonable expectation of success. We report here our early results of heart transplantation in 11 patients with malignant disease. Our survival rate in this group is 100%, and all patients are leading active lives with no evidence of recurrent or metastatic tumor. Immunosuppression protocols were adjusted on an individual basis determined by the chemotherapy dosage, duration, and relation to transplantation. Whenever possible a 1-year disease-free interval after completion of adequate cancer therapy is desired before transplantation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2277299

Source DB:  PubMed          Journal:  J Heart Transplant        ISSN: 0887-2570


  8 in total

1.  Anthracycline-induced cardiomyopathy.

Authors:  N G Fisher; A J Marshall
Journal:  Postgrad Med J       Date:  1999-05       Impact factor: 2.401

Review 2.  Anthracyclines and the heart.

Authors:  W Rhoden; P Hasleton; N Brooks
Journal:  Br Heart J       Date:  1993-12

3.  Long-term follow-up of hearttransplant recipients with pre-transplant malignancies.

Authors:  Samuel D Ladowski; Milinda Abel; Linda Beatty; Margaret Scatena; Joseph S Ladowski
Journal:  Tex Heart Inst J       Date:  2006

4.  Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin.

Authors:  S Sriskandan; M E O'Brien; I E Smith; P Collins; M E Gore
Journal:  Postgrad Med J       Date:  1994-10       Impact factor: 2.401

5.  Pre-transplant malignancy: an analysis of outcomes after thoracic organ transplantation.

Authors:  Claude A Beaty; Timothy J George; Arman Kilic; John V Conte; Ashish S Shah
Journal:  J Heart Lung Transplant       Date:  2012-12-21       Impact factor: 10.247

6.  Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.

Authors:  A Llombart-Cussac; X Pivot; G Contesso; A Rhor-Alvarado; J P Delord; M Spielmann; T Türsz; A Le Cesne
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

Review 7.  Severe Cardiac Toxicity Induced by Cancer Therapies Requiring Intensive Care Unit Admission.

Authors:  Andrea Montisci; Vittorio Palmieri; Jennifer E Liu; Maria T Vietri; Silvia Cirri; Francesco Donatelli; Claudio Napoli
Journal:  Front Cardiovasc Med       Date:  2021-09-03

8.  Survival after heart transplantation for non-metastatic primary cardiac sarcoma.

Authors:  Hua Li; Shouguo Yang; Hao Chen; Zhaohua Yang; Tao Hong; Yingyong Hou; Chunsheng Wang
Journal:  J Cardiothorac Surg       Date:  2016-10-03       Impact factor: 1.637

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.